Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue$4.37M$4.37M+13.9% vs Q1 2018 Net Income-$3.46M-$3.46MN/M vs Q1 2018 EPS Diluted-$4.99-$4.99no prior Q1 2018 on file Gross Profit$1,731,000−1.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$3,060,000N/M Free Cash Flowderived-$3,087,000N/M Margins · derivedGross margin39.6%−6.3 pt vs Q1 2018
Operating margin-81.3%+6.9 pt vs Q1 2018
Net margin-79.1%+12.3 pt vs Q1 2018
ended Jun 30, 2018 · filed Aug 8, 2018 · 39 d after period end